SCHEMBL23266201

SCHEMBL23266201

CC(C)=CCOc1ccc(CCCCO)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.47
EPHX2 P34913 1/20 0.47
NDUFS8 O00217 1/20 0.47
COXFA4 O00483 1/20 0.47
NDUFAB1 O14561 1/20 0.47
NDUFA1 O15239 1/20 0.47
NDUFS4 O43181 1/20 0.47
NDUFB5 O43674 1/20 0.47
NDUFB3 O43676 1/20 0.47
NDUFC1 O43677 1/20 0.47
NDUFA2 O43678 1/20 0.47
NDUFS5 O43920 1/20 0.47
NDUFS7 O75251 1/20 0.47
NDUFS2 O75306 1/20 0.47
NDUFS6 O75380 1/20 0.47
NDUFB1 O75438 1/20 0.47
NDUFS3 O75489 1/20 0.47
NDUFB6 O95139 1/20 0.47
NDUFA3 O95167 1/20 0.47
NDUFB4 O95168 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18265469 0.95 LTA4H (0.53) LTA4HEPHX2NDUFS8COXFA4NDUFAB1
Etrogol SCHEMBL18265493 0.88 NDUFS8 (0.50) LTA4HEPHX2NDUFS8COXFA4NDUFAB1
SCHEMBL11570459 0.81 NDUFS8 (0.46) LTA4HNDUFS8COXFA4NDUFAB1NDUFA1
SCHEMBL23266200 0.81 NDUFS8 (0.48) NDUFS8COXFA4NDUFAB1NDUFA1NDUFS4
SCHEMBL8036010 0.80 KDM4E (0.53) NDUFS8COXFA4NDUFAB1NDUFA1NDUFS4
SCHEMBL25806392 0.80 TAAR1 (0.52) NDUFS8COXFA4NDUFAB1NDUFA1NDUFS4
SCHEMBL23642842 0.80 LTA4H (0.50) LTA4HEPHX2ALDH1A1MEN1USP2
SCHEMBL8618406 0.79 LTA4H (0.50) LTA4HEPHX2ALDH1A1MEN1USP2
SCHEMBL9262789 0.78 ALDH1A1 (0.50) ALDH1A1MEN1LMNACYP3A4KMT2A
SCHEMBL9026418 0.78 KMT2A (0.55) LTA4HEPHX2ALDH1A1MEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11325937-B2 Glycoside compound and preparation method therefor, composition, application, and intermediate SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) 2022-05-10 US disclosed
EP-3819303-A1 GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE Shanghai Hutchison Pharmaceuticals Limited (CN) 2021-05-12 EP disclosed
US-20210115082-A1 GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED (CN) 2021-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11325937-B2 Glycoside compound and preparation method therefor, composition, application, and intermediate VEGFA, FLT4, FLT1 LTA4H 2112/4885EPHX2 2972/4885NDUFS8 781/4885
US-20210115082-A1 GLYCOSIDE COMPOUND AND PREPARATION METHOD THEREFOR, COMPOSITION, APPLICATION, AND INTERMEDIATE VEGFA, FLT4, FLT1 LTA4H 2112/4885EPHX2 2972/4885NDUFS8 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.